CML: COVID-19 May Be Fatal in More Than 5% of Patients
The mortality rate was 0.13% in the overall chronic myeloid leukemia cohort.
Diagnosis & Disease Information
Response-Based Ponatinib Dosing Appears Effective in Chronic Phase Chronic Myeloid Leukemia
A 45-mg starting dose, reduced to 15 mg, produced the best outcome.
Chronic Myeloid Leukemia: What Your Patients Need to Know
Chronic myeloid leukemia (CML) can be painful and life-threatening if it is not caught in time. How can you educate patients with symptoms or who are newly diagnosed about the detection, symptoms, risk factors, and treatment of CML?
Leukemia: Fact Sheet for Patients
Almost everyone has heard of leukemia, but most people do not have a good understanding of this complex disease. How can healthcare providers explain the basics of leukemia to their patients?
Iclusig Approved for Resistant or Intolerant Chronic-Phase CML
The sNDA approval is based on efficacy and safety data from the open-label phase 2 OPTIC trial and 5-year data from the phase 2 PACE trial.
Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Study results suggested that the discontinuation of tyrosine kinase inhibitors for chronic myeloid leukemia may be safe, without limiting remission.
British Society for Haematology Guideline Update for the Diagnosis and Management of Chronic Myeloid Leukemia
The British Society for Haematology has published updated guidelines for the diagnosis and management of chronic myeloid leukemia in adults and children.
First-line Therapy Response vs Switching Treatments in Chronic Myeloid Leukemia
CP-CML patients who remain on first-line TKI therapy have better clinical responses than patients who switch within the first 3 years.
Patients With CML Continue to Be Prescribed Costly Second-Gen TKIs
Most patients with CML are being prescribed costly second-generation TKIs, even though generic imatinib has been available since 2016.
Study Provides Support for TKI Discontinuation in Some Patients With CML
This population-based study of patients with chronic phase CML evaluated the BCR/ABL1 TKI discontinuation rates for patients treated on and off a clinical trial.
- Loading...
Loading...
Next post in EHA25 Virtual Congress
Loading... 
Loading...